keyword
MENU ▼
Read by QxMD icon Read
search

Her2 positive breast cancer

keyword
https://www.readbyqxmd.com/read/29148091/intrinsic-subtypes-of-breast-cancers-initially-assessed-as-probably-benign-or-of-low-suspicion-on-ultrasonography-differ-according-to-tumor-size
#1
Jieun Koh, Min Jung Kim, Hee Jung Moon, Jung Hyun Yoon, Vivian Youngjean Park, Eun-Kyung Kim
OBJECTIVES: To investigate whether the intrinsic subtypes of breast cancers initially assessed as American College of Radiology Breast Imaging and Reporting System (BI-RADS) category 3 or 4a differ according to tumor size. METHODS: A total of 444 breast cancers in 439 patients initially assessed as BI-RADS 3 or 4a through ultrasound-guided core needle biopsy were included. Tumors were classified by the size criterion of 10 mm or smaller or larger than 10 mm and categorized as the luminal type (estrogen receptor [ER] positive and/or progesterone receptor [PR] positive and human epidermal growth factor receptor 2 [HER2] negative), HER2 type (HER2 positive regardless of ER or PR status), or triple-negative type (ER negative, PR negative, and HER2 negative)...
November 17, 2017: Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine
https://www.readbyqxmd.com/read/29147072/paradoxical-association-of-postoperative-plasma-sphingosine-1-phosphate-with-breast-cancer-aggressiveness-and-chemotherapy
#2
Rajesh Ramanathan, Ali Raza, Jamie Sturgill, Debra Lyon, Jessica Young, Nitai C Hait, Kazuaki Takabe
Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator that has been shown to serve an important regulatory function in breast cancer progression. This study analyzes plasma S1P levels in breast cancer patients undergoing adjuvant therapy as compared to healthy control volunteers. 452 plasma S1P samples among 158 breast cancer patients, along with 20 healthy control volunteers, were analyzed. Mean S1P levels did not significantly differ between cancer patients and controls. Smoking was associated with higher S1P levels in cancer patients...
2017: Mediators of Inflammation
https://www.readbyqxmd.com/read/29146695/first-in-human-her2-targeted-imaging-using-89-zr-pertuzumab-pet-ct-dosimetry-and-clinical-application-in-patients-with-breast-cancer
#3
Gary A Ulaner, Serge K Lyashchenko, Christopher Riedl, Shutian Ruan, Pat B Zanzonico, Diana Lake, Komal Jhaveri, Brian Zeglis, Jason S Lewis, Joseph A O'Donoghue
In this first-in-human study, we evaluate the safety and dosimetry of (89)Zr-pertuzumab PET/CT for HER2-targeted imaging in patients with HER2-postive breast cancer. Materials and Methods: Patients with HER2-positive breast cancer and evidence of distant metastases were enrolled in an Institutional Review Board (IRB)-approved prospective clinical trial. Pertuzumab was conjugated with deferoxamine and radiolabeled with (89)Zr. Patients underwent (89)Zr-pertuzumab PET/CT with 74 MBq of (89)Zr-pertuzumab in a total antibody mass of 20-50 mg of pertuzumab...
November 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29146401/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast-cancer-extenet-5-year-analysis-of-a-randomised-double-blind-placebo-controlled-phase-3-trial
#4
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Stephen K L Chia, Janine Mansi, Carlos H Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Erhan Gokmen, Anna Bashford, Manuel Ruiz Borrego, Sung-Bae Kim, Erik Hugger Jakobsen, Audrone Ciceniene, Kenichi Inoue, Friedrich Overkamp, Joan B Heijns, Anne C Armstrong, John S Link, Anil Abraham Joy, Richard Bryce, Alvin Wong, Susan Moran, Bin Yao, Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan
BACKGROUND: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings. METHODS: In this ongoing randomised, double-blind, placebo-controlled, phase 3 trial, eligible women aged 18 years or older (≥20 years in Japan) with stage 1-3c (modified to stage 2-3c in February, 2010) operable breast cancer, who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab with no evidence of disease recurrence or metastatic disease at study entry...
November 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29146400/extended-adjuvant-therapy-in-patients-with-her2-positive-breast-cancer-some-answers-even-more-questions
#5
Mariana Chavez-MacGregor, Elizabeth A Mittendorf
No abstract text is available yet for this article.
November 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29146052/phenotypic-alterations-in-breast-cancer-associated-with-neoadjuvant-chemotherapy-a-comparison-with-baseline-rates-of-change
#6
Nosaibah Hariri, Andres A Roma, Farnaz Hasteh, Vighnesh Walavalkar, Oluwole Fadare
Several studies have documented phenotypic alterations in breast cancer associated with neoadjuvant chemotherapy [NACT], but many of these studies are limited by the fact that they did not account for the baseline rate of expected phenotypic change between biopsies and resections in the absence of NACT. Herein, we assess whether the NACT-associated rate of phenotypic change is significantly different than would be expected in a control population of patients that did not receive NACT. From a pathologic database, we documented the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2/neu) phenotypes of consecutive invasive breast carcinomas (n=826), as well as the subset in which at least one of these tests was assessed in both the biopsy and resection (n=340)...
December 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29142802/metastatic-her2-breast-cancer-a-potentially-curable-disease
#7
Lisa Prior, Marvin Lim, Cian Ward, Hannah Featherstone, Hazel Murray, Clare D'Arcy, John Crown, Giuseppe Gullo
The advent of trastuzumab and other human epidermal growth factor receptor 2 (HER2)-directed therapies has revolutionized the treatment of metastatic HER2-positive breast cancer, leading to prolonged survival and appreciable clinical benefit for a substantial subset of patients. Previously, in a retrospective study at our institution, we observed that nearly 10% of patients achieved a durable complete remission (DCR) following a combination of HER2-directed therapy and cytotoxic chemotherapy. We are currently expanding this study to include patients who were treated since the initial introduction of trastuzumab...
September 5, 2017: Curēus
https://www.readbyqxmd.com/read/29142588/characterization-of-hormonal-receptors-and-human-epidermal-growth-factor-receptor-2-in-tissues-of-women-with-breast-cancer-at-muhimbili-national-hospital-dar-es-salaam-tanzania
#8
Amos Rodger Mwakigonja, Nyanda Elias Lushina, Ally Mwanga
Background: Breast cancer is a leading cause of morbidity and deaths among women worldwide. In Tanzania there is no published data on human epidermal growth receptor-2 (HER2/neu) expression in breast carcinoma. Hormonal receptors and HER2/neu status reportedly influence post-mastectomy adjuvant therapy and predict treatment outcome and prognosis. Here we evaluate hormonal receptors and HER-2 status in biopsies of women with breast cancer at Muhimbili National Hospital (MNH). Methods: A cross-sectional study of female breast post-modified radical mastectomy (MRM)/incisional biopsies confirmed to be carcinoma at the Histopathology Unit (January-December 2013)...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/29142051/improved-detection-of-her2-by-a-quasi-targeted-proteomics-approach-using-aptamer-peptide-probe-and-liquid-chromatography-tandem-mass-spectrometry
#9
Weixian Zhou, Feifei Xu, Danni Li, Yun Chen
BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive type of the disease. To date, much evidence has indicated that accurate HER2 status detection is crucial for prognosis and treatment strategy selection. Thus, bioanalytical techniques for early and accurate detection of HER2 have the potential to improve patient care. Currently, the widely used immunohistochemical staining normally has problems with reproducibility and lack of standardization, resulting in poor concordance between laboratories...
November 15, 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/29141852/collagen-alignment-as-a-predictor-of-recurrence-after-ductal-carcinoma-in-situ
#10
Matthew W Conklin, Ronald E Gangnon, Brian L Sprague, Lisa van Germert, John M Hampton, Kevin W Eliceiri, Jeremy S Bredfeldt, Yuming Liu, Nuntida Surachaicharn, Polly A Newcomb, Andreas Friedl, Patricia Keely, Amy Trentham-Dietz
BACKGROUND: Collagen fibers surrounding breast ducts may influence breast cancer progression. Syndecan-1 interacts with constituents in the extracellular matrix, including collagen fibers, and may contribute to cancer cell migration. Thus, the orientation of collagen fibers surrounding ductal carcinoma in situ (DCIS) lesions and stromal syndecan-1 expression may predict recurrence. METHODS: We evaluated collagen fiber alignment and syndecan-1 expression in 227 women diagnosed with DCIS in 1995-2006 followed through 2014 (median 14...
November 15, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/29138761/a-metastasis-biomarker-metasite-breast%C3%A2-score-is-associated-with-distant-recurrence-in-hormone-receptor-positive-her2-negative-early-stage-breast-cancer
#11
Joseph A Sparano, Robert Gray, Maja H Oktay, David Entenberg, Thomas Rohan, Xiaonan Xue, Michael Donovan, Michael Peterson, Anthony Shuber, Douglas A Hamilton, Timothy D'Alfonso, Lori J Goldstein, Frank Gertler, Nancy E Davidson, John Condeelis, Joan Jones
Metastasis is the primary cause of death in early-stage breast cancer. We evaluated the association between a metastasis biomarker, which we call "Tumor Microenviroment of Metastasis" (TMEM), and risk of recurrence. TMEM are microanatomic structures where invasive tumor cells are in direct contact with endothelial cells and macrophages, and which serve as intravasation sites for tumor cells into the circulation. We evaluated primary tumors from 600 patients with Stage I-III breast cancer treated with adjuvant chemotherapy in trial E2197 (NCT00003519), plus endocrine therapy for hormone receptor (HR)+ disease...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29138067/the-prognostic-effect-of-changes-in-tumor-stage%C3%A2-and-nodal-status-after-neoadjuvant-chemotherapy-in-each-primary-breast-cancer%C3%A2-subtype
#12
Naoki Hayashi, Yuko Takahashi, Naoko Matsuda, Hiroko Tsunoda, Atsushi Yoshida, Koyu Suzuki, Seigo Nakamura, Hideko Yamauchi
BACKGROUND: Although the prognostic value of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) depends on the intrinsic subtype of breast cancer, it is not clear whether chemosensitivity itself, shown by a decreasing tumor burden after NAC, contributes to improved prognosis in primary breast cancer patients, especially in patients with non-pCR. The aim of this study was to assess the prognostic effect of changes in tumor stage or nodal status after NAC in each primary breast cancer subtype...
October 3, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29137653/prognostic-value-of-pam50-and-risk-of-recurrence-score-in-patients-with-early-stage-breast-cancer-with-long-term-follow-up
#13
Hege O Ohnstad, Elin Borgen, Ragnhild S Falk, Tonje G Lien, Marit Aaserud, My Anh T Sveli, Jon A Kyte, Vessela N Kristensen, Gry A Geitvik, Ellen Schlichting, Erik A Wist, Therese Sørlie, Hege G Russnes, Bjørn Naume
BACKGROUND: The aim of this study was to investigate the prognostic value of the PAM50 intrinsic subtypes and risk of recurrence (ROR) score in patients with early breast cancer and long-term follow-up. A special focus was placed on hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) pN0 patients not treated with chemotherapy. METHODS: Patients with early breast cancer (n = 653) enrolled in the observational Oslo1 study (1995-1998) were followed for distant recurrence and breast cancer death...
November 14, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29137369/lrh-1-expression-patterns-in-breast-cancer-tissues-are-associated-with-tumour-aggressiveness
#14
Jia-Min B Pang, Ramyar Molania, Ashwini Chand, Kevin Knower, Elena A Takano, David J Byrne, Thomas Mikeska, Ewan K A Millar, Cheok Soon Lee, Sandra A O'Toole, Colin Clyne, Kylie L Gorringe, Alexander Dobrovic, Stephen B Fox
The significance and regulation of liver receptor homologue 1 (LRH-1, NR5A2), a tumour-promoting transcription factor in breast cancer cell lines, is unknown in clinical breast cancers. This study aims to determine LRH-1/NR5A2 expression in breast cancers and relationship with DNA methylation and tumour characteristics. In The Cancer Genome Atlas breast cancer cohort NR5A2 expression was positively associated with intragenic CpG island methylation (1.4-fold expression for fully methylated versus not fully methylated, p=0...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29136405/survival-outcomes-for-australian-women-receiving-trastuzumab-for-her2-positive-metastatic-breast-cancer-following-neo-adjuvant-trastuzumab-a-national-population-based-observational-study-2006-2014
#15
Benjamin Daniels, Belinda E Kiely, Nehmat Houssami, Sarah J Lord, Timothy Dobbins, Christine Y Lu, Robyn L Ward, Sallie-Anne Pearson
BACKGROUND: Patients treated with (neo)adjuvant trastuzumab who relapse and receive trastuzumab for metastatic breast cancer (MBC) are a growing population with little outcome data given their exclusion from most clinical trials. We aim to estimate survival outcomes for this trastuzumab 'pre-treated' population. METHODS: Population-based study of Australian women receiving trastuzumab for HER2-positive MBC between 2006 and 2014, who also received (neo)adjuvant trastuzumab...
November 14, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29135722/assessment-of-biological-and-clinical-aggressiveness-of-invasive-ductal-breast-cancer-using-baseline-18f-fdg-pet-ct-derived-volumetric-parameters
#16
Gul Ege Aktas, Ebru Taştekin, Ali Sarikaya
OBJECTIVE: The aim of this study was to evaluate the relationship of baseline fluorine-18-fluorodeoxyglucose PET/computed tomography (CT)-derived volumetric parameters for the primary tumor with clinicopathological risk factors and molecular subtypes in patients with invasive ductal breast carcinoma (IDBC). PATIENTS AND METHODS: We evaluated 65 patients who underwent fluorine-18-fluorodeoxyglucose PET/CT for initial breast cancer staging. The association of maximum and mean standardized uptake values (SUVmax and SUVmean, respectively), metabolic tumor volume, and total lesion glycolysis (TLG) with clinicopathological risk factors and molecular subtypes was investigated and the discriminative power of significant features was assessed...
November 10, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29133620/evaluation-of-cdk12-protein-expression-as-a-potential-novel-biomarker-for-dna-damage-response-targeted-therapies-in-breast-cancer
#17
Kalnisha Naidoo, Patty T Wai, Sarah L Maguire, Frances Daley, Syed Haider, Divya Kriplani, James Campbell, Hasan Mirza, Anita Grigoriadis, Andrew Tutt, Paul M Moseley, Tarek M A Abdel-Fatah, Stephen Yt Chan, Srinivasan Madhusudan, Emad A Rakha, Ian O Ellis, Christopher J Lord, Yinyin Yuan, Andrew R Green, Rachael Natrajan
Disruption of Cyclin Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and poly(ADP-ribose) polymerase 1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. We therefore aimed to assess the frequency and distribution of CDK12 protein expression by immunohistochemistry (IHC) in independent cohorts of breast cancer and correlate this with outcome and genomic status. We found that 21% of primary unselected breast cancers were CDK12 high, and 10...
November 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29133514/first-prospective-multicenter-italian-study-on-the-impact-of-the-21-gene-recurrence-score-in-adjuvant-clinical-decisions-for-patients-with-er-positive-her2-negative-breast-cancer
#18
Maria Vittoria Dieci, Valentina Guarneri, Tommaso Giarratano, Marta Mion, Giampaolo Tortora, Costanza De Rossi, Stefania Gori, Cristina Oliani, Laura Merlini, Felice Pasini, Giorgio Bonciarelli, Gaia Griguolo, Enrico Orvieto, Silvia Michieletto, Tania Saibene, Paola Del Bianco, Gian Luca De Salvo, PierFranco Conte
BACKGROUND: The Breast DX Italy prospective study evaluated the impact of the 21-gene recurrence score (RS) result on adjuvant treatment decisions for patients with early breast cancer. MATERIALS AND METHODS: Nine centers (two Hub and seven Spoke centers of the Veneto Oncology Network) participated. Consecutive patients with estrogen receptor positive, human epidermal growth receptor negative, T1-T3, N0-N1 early breast cancer were prospectively registered; only those meeting protocol-defined clinicopathological "intermediate risk" criteria were eligible for the RS test...
November 13, 2017: Oncologist
https://www.readbyqxmd.com/read/29132567/lobular-breast-cancer-different-disease-different-algorithms
#19
REVIEW
Anita Mamtani, Tari A King
Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, with a unique pathogenesis and distinct clinical biology. ILCs display a characteristic loss of E-cadherin, are largely estrogen receptor positive, HER2 negative, and low to intermediate grade. These features portend a favorable prognosis, but there is a tendency for late recurrences and atypical metastases. ILCs tend to be insidious and infiltrative, which can pose a challenge for diagnosis, and emerging data suggest they may have a propensity for a differing response to standard therapies...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29131988/treatment-adoption-and-relative-effectiveness-of-aromatase-inhibitors-compared-to-tamoxifen-in-early-breast-cancer-a-multi-institutional-observational-study
#20
Arlindo R Ferreira, Ana Palha, Lurdes Correia, Pedro Filipe, Vasco Rodrigues, Ana Miranda, Rosário André, João Fernandes, Joaquim Gouveia, José L Passos-Coelho, António Moreira, Margarida Brito, Joana Ribeiro, Otto Metzger-Filho, Nancy U Lin, Luís Costa, Inês Vaz-Luis
BACKGROUND: Since 2005, aromatase inhibitors (AIs) have been the adjuvant treatment of choice for postmenopausal women with early breast cancer (BC). In this study we characterize the adoption of AIs in Portugal, variables associated with treatment administration, and compare its effectiveness (either in monotherapy or sequential therapy) to tamoxifen monotherapy (TAM). PATIENTS AND METHODS: This was a retrospective cohort study that included postmenopausal women with stage I-III hormone receptor (HR) positive BC diagnosed from 2006 to 2008 and treated with adjuvant endocrine therapy in four participating institutions...
November 10, 2017: Breast: Official Journal of the European Society of Mastology
keyword
keyword
59406
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"